Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 41-46

  Matulonis, Ursula A ^a   Pereira, Lauren ^a   Liu, Joyce ^a   Lee, Hang ^b   Lee, Julie ^a   Whalen, Christin ^a   Campos, Susana ^a   Atkinson, Tina ^a   Hill, Margaret ^a   Berlin, Suzanne ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti angiogenic agents; Bevacizumab; Metronomic therapy; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE;

ADULT; AGED; ANGIOGENESIS; ARTHRALGIA; ARTICLE; BACKACHE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INTESTINE PERFORATION; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; STOMACH PERFORATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862765843     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.003     Document Type: Article

References (34)

1. McGuire WP, Hoskins WJ, Brade MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
2. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27(9):1419-25.
3. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120-5. (Pubitemid 41103725)
4. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol Jun 1997;15(6):2183-93. (Pubitemid 27251118)
5. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 Jul 15;19(14):3312-22. (Pubitemid 32642183)
6. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007;25:2894-901. (Pubitemid 47123153)
7. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71. (Pubitemid 350237599)
8. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;5:5180-6. (Pubitemid 350232248)
9. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 Dec 29;365(26):2473-83.
10. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-6.
11. Matel D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011;29(1):69-75.
12. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22:335-40.
13. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32-7.
14. Matulonis U, Tew WP, Matei D, Behbakht K, Fleming GF, Oza AM, et al. A phase II study of ENMD2076 in platinum-resistant ovarian cancer [abstract 5021]. In Proceedings of the 2011 American Society of Clinical Oncology meeting, 2011.
15. Vergote I, Sella A, Bedell C, Ramondetta L, Shapiro G, Balic K, et al. Phase II study of XL184 in a cohort of ovarian cancer patients with measurable soft tissue disease [Abstract 407]. Proceedings of the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics conference; 2010.
16. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-804.
17. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36. (Pubitemid 38745528)
18. Kerbel RS. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res Treat 2007;39:150-9.
19. Hanahan D, Bergers G, Bergland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target angiogenesis in mice. J Clin Invest 2000;105:1045-7. (Pubitemid 30217688)
20. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86. (Pubitemid 30207647)
21. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24. (Pubitemid 30217701)
22. Aghajanian C, Finkler NJ, Rutherford T, Smith DA, Yi J, Parmar H, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2011;29 (Suppl.; abstr LBA5007).
23. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubenstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNCI 2000;92:205-16.
25. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a Trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J Clin Oncol 2008;26:76-82.
26. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-34.
27. Chura JC, Van Iseghem K, Downs LS, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007;107:326-30. (Pubitemid 47575735)
28. Watanabe Y, Etoh T, Koike E, Mizuno Y, Wang WM, Hoshiai H, et al. Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial cancer. Int J Clin Oncol 2010;15:468-71.
29. Samaritani R, Corrado G, Vizza E, Sbiroli C. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer 2007;15(7):65.
30. Eichbaum M, Mayer C, Eichhoff R, Bischofs E, Gebauer G, Fehm T, et al. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer 2011;11:453.
31. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncology 2008;26:3709-14.
32. Burstein HJ, Spigel D, Kinds Vogel K, Vogel K, Parker LM, Bunnell CA, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005;92(1 s) (Suppl. abstract 4).
33. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 2010;9:985-95.
34. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9:996-1006.